News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
The Danish biotech company Antag Therapeutics announced yesterday that it had raised €80 million ($84 million) in a Series A financing round to boost the clinical development of its next-generation weight loss therapy, AT-7687.
MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.
The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the chronic skin condition.
Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.
Clinical trial results have revealed that semaglutide treatment significantly reduced hospital admissions in overweight and obese adults with heart disease.
Dandelion Health used its new clinical AI marketplace to analyze real-world data, showing that GLP-1 drugs may help prevent cardiovascular disease (CVD) for a seven times larger population than previously researched.
With a new investment in its two manufacturing sites in Ireland, Eli Lilly continues implementing the largest expansion program in the company’s history.
Rachel Sha has had a colorful career not without its challenges, but she urges women in the science industry to have confidence and answer hard questions.
Results from a phase 2b clinical trial in the UK have shown that Novo Nordisk’s GLP-1 drug liraglutide can protect the brain against dementia.